Browsing by Author "Carpenter, John T."

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008
    (Springer Nature, 2018-01) Connolly, Roisin M.; Fackler, Mary Jo; Zhang, Zhe; Zhou, Xian C.; Goetz, Matthew P.; Boughey, Judy C.; Walsh, Bridget; Carpenter, John T.; Storniolo, Anna Maria; Watkins, Stanley P.; Gabrielson, Edward W.; Stearns, Vered; Sukumar, Saraswati; Medicine, School of Medicine
    BACKGROUND: Methylated gene markers have shown promise in predicting breast cancer outcomes and treatment response. We evaluated whether baseline and changes in tissue and serum methylation levels would predict pathological complete response (pCR) in patients with HER2-negative early breast cancer undergoing preoperative chemotherapy. METHODS: The TBCRC008 trial investigated pCR following 12 weeks of preoperative carboplatin and albumin-bound paclitaxel + vorinostat/placebo (n = 62). We measured methylation of a 10-gene panel by quantitative multiplex methylation-specific polymerase chain reaction and expressed results as cumulative methylation index (CMI). We evaluated association between CMI level [baseline, day 15 (D15), and change] and pCR using univariate and multivariable logistic regression models controlling for treatment and hormone receptor (HR) status, and performed exploratory subgroup analyses. RESULTS: In univariate analysis, one log unit increase in tissue CMI levels at D15 was associated with 40% lower chance of obtaining pCR (odds ratio, OR 0.60, 95% CI 0.37-0.97; p = 0.037). Subgroup analyses suggested a significant association between tissue D15 CMI levels and pCR in vorinostat-treated [OR 0.44 (0.20, 0.93), p = 0.03], but not placebo-treated patients. CONCLUSION: In this study investigating the predictive roles of tissue and serum CMI levels in patients with early breast cancer for the first time, we demonstrate that high D15 tissue CMI levels may predict poor response. Larger studies and improved analytical procedures to detect methylated gene markers in early stage breast cancer are needed. TBCRC008 is registered on ClinicalTrials.gov (NCT00616967).